BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21822119)

  • 21. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma.
    Kaiser M; Zavrski I; Sterz J; Jakob C; Fleissner C; Kloetzel PM; Sezer O; Heider U
    Haematologica; 2006 Feb; 91(2):248-51. PubMed ID: 16461312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
    Gao D; Xia Q; Lv J; Zhang H
    Int J Urol; 2007 Sep; 14(9):838-45. PubMed ID: 17760752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors.
    Cho HH; Park HT; Kim YJ; Bae YC; Suh KT; Jung JS
    J Cell Biochem; 2005 Oct; 96(3):533-42. PubMed ID: 16088945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
    Iwata S; Saito T; Ito Y; Kamakura M; Gotoh K; Kawada J; Nishiyama Y; Kimura H
    Cancer Sci; 2012 Feb; 103(2):375-81. PubMed ID: 22017376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells.
    Juengel E; Dauselt A; Makarević J; Wiesner C; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    Cancer Lett; 2012 Nov; 324(1):83-90. PubMed ID: 22579787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valproic acid-mediated neuroprotection in retinal ischemia injury via histone deacetylase inhibition and transcriptional activation.
    Zhang Z; Qin X; Tong N; Zhao X; Gong Y; Shi Y; Wu X
    Exp Eye Res; 2012 Jan; 94(1):98-108. PubMed ID: 22143029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
    Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P
    Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased replication of human cytomegalovirus in retinal pigment epithelial cells by valproic acid depends on histone deacetylase inhibition.
    Michaelis M; Suhan T; Reinisch A; Reisenauer A; Fleckenstein C; Eikel D; Gümbel H; Doerr HW; Nau H; Cinatl J
    Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3451-7. PubMed ID: 16123451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells.
    Wu Y; Guo SW
    Eur J Obstet Gynecol Reprod Biol; 2008 Apr; 137(2):198-203. PubMed ID: 17376583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of sodium valproate on proliferation and apoptosis of human myelodysplastic syndromes cell line MUTZ-1].
    Chen BA; Zhao HH; Gao C; Shao ZY; Xia GH; Dohner K
    Ai Zheng; 2007 Dec; 26(12):1323-9. PubMed ID: 18076794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells.
    Fortunati N; Bertino S; Costantino L; Bosco O; Vercellinatto I; Catalano MG; Boccuzzi G
    Cancer Lett; 2008 Feb; 259(2):156-64. PubMed ID: 18006146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
    Xia Q; Sung J; Chowdhury W; Chen CL; Höti N; Shabbeer S; Carducci M; Rodriguez R
    Cancer Res; 2006 Jul; 66(14):7237-44. PubMed ID: 16849572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.
    Baumann P; Junghanns C; Mandl-Weber S; Strobl S; Oduncu F; Schmidmaier R
    Br J Haematol; 2012 Mar; 156(5):633-42. PubMed ID: 22211565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
    Shoji M; Ninomiya I; Makino I; Kinoshita J; Nakamura K; Oyama K; Nakagawara H; Fujita H; Tajima H; Takamura H; Kitagawa H; Fushida S; Harada S; Fujimura T; Ohta T
    Int J Oncol; 2012 Jun; 40(6):2140-6. PubMed ID: 22469995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Inhibitory effect of valproic acid on xenografted Kasumi-1 tumor growth in nude mouse and its mechanism].
    Liu P; Tian X; Shi GR; Jiang FY; Liu BQ; Zhang ZH; Zhao L; Yan LN; Liang ZQ; Hao CL
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):458-62. PubMed ID: 22213865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells.
    Greenblatt DY; Vaccaro AM; Jaskula-Sztul R; Ning L; Haymart M; Kunnimalaiyaan M; Chen H
    Oncologist; 2007 Aug; 12(8):942-51. PubMed ID: 17766653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HDAC inhibition is associated to valproic acid induction of early megakaryocytic markers.
    Vulcano F; Ciccarelli C; Mattia G; Marampon F; Giampiero M; Milazzo L; Pascuccio M; Zani BM; Giampaolo A; Hassan HJ
    Exp Cell Res; 2006 May; 312(9):1590-7. PubMed ID: 16739251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo.
    Machado MC; Bellodi-Privato M; Kubrusly MS; Molan NA; Tharcisio T; de Oliveira ER; D'Albuquerque LA
    J Exp Ther Oncol; 2011; 9(2):85-92. PubMed ID: 21699015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of valproic acid-initiated homologous recombination.
    Sha K; Winn LM
    Birth Defects Res B Dev Reprod Toxicol; 2010 Apr; 89(2):124-32. PubMed ID: 20437471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.